{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T23:42:21Z","timestamp":1794699741132,"version":"4.9.1"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["27265"],"award-info":[{"award-number":["27265"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01079-1","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:45:05Z","timestamp":1755737105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system"],"prefix":"10.1038","volume":"9","author":[{"given":"Alba Clara","family":"Fern\u00e1ndez-Rilo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"de Billy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Del Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Del Bufalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Quintarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Mastronuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"1079_CR1","doi-asserted-by":"publisher","first-page":"100476","DOI":"10.1016\/j.jlr.2023.100476","volume":"64","author":"R Sandhoff","year":"2023","unstructured":"Sandhoff, R. Lipid structure matters in lysosomal storage disease. J. Lipid. Res. 64, 100476 (2023).","journal-title":"J. Lipid. Res."},{"key":"1079_CR2","doi-asserted-by":"publisher","first-page":"12082","DOI":"10.1016\/S0021-9258(19)49809-8","volume":"267","author":"Y Nagata","year":"1992","unstructured":"Nagata, Y. et al. Expression cloning of \u03b21,4 N-acetylgalactosaminyltransferase cDNAs that determine the expression of GM2 and GD2 gangliosides. J. Biol. Chem. 267, 12082\u201312089 (1992).","journal-title":"J. Biol. Chem."},{"key":"1079_CR3","doi-asserted-by":"publisher","first-page":"16200","DOI":"10.1016\/S0021-9258(18)41986-2","volume":"267","author":"ER Sjoberg","year":"1992","unstructured":"Sjoberg, E. R., Manzi, A. E., Khoo, K. H., Dell, A. & Varki, A. Structural and immunological characterization of O-acetylated GD2: evidence that GD2 is an acceptor for ganglioside O-acetyltransferase in human melanoma cells. J. Biol. Chem. 267, 16200\u201316211 (1992).","journal-title":"J. Biol. Chem."},{"key":"1079_CR4","doi-asserted-by":"publisher","unstructured":"Thomas, P. et al. Targeting pediatric High-Grade Gliomas with O AcGD2-CAR V\u03b42 T cells. Preprint at https:\/\/doi.org\/10.1101\/2023.11.17.567375 (2023).","DOI":"10.1101\/2023.11.17.567375"},{"key":"1079_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00262-021-02963-y","volume":"71","author":"R Tibbetts","year":"2022","unstructured":"Tibbetts, R. et al. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance. Cancer Immunol. Immunother. 71, 153\u2013164 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"1079_CR6","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1073\/pnas.86.13.5146","volume":"86","author":"UC Wargalla","year":"1989","unstructured":"Wargalla, U. C. & Reisfeld, R. A. Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc. Natl. Acad. Sci. USA. 86, 5146\u20135150 (1989).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1079_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fimmu.2014.00325","volume":"5","author":"U Krengel","year":"2014","unstructured":"Krengel, U. & Bousquet, P. A. Molecular recognition of gangliosides and their potential for cancer immunotherapies. Front. Immunol. 5, 325 (2014).","journal-title":"Front. Immunol."},{"key":"1079_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrc1014","volume":"3","author":"GM Brodeur","year":"2003","unstructured":"Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3, 203\u2013216 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"1079_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.sbi.2009.06.001","volume":"19","author":"PHH Lopez","year":"2009","unstructured":"Lopez, P. H. H. & Schnaar, R. L. Gangliosides in cell recognition and membrane protein regulation. Curr. Opin. Struct. Biol. 19, 549\u2013557 (2009).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"1079_CR10","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1172\/JCI59735","volume":"122","author":"VL Battula","year":"2012","unstructured":"Battula, V. L. et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J. Clin. Investig. 122, 2066\u20132078 (2012).","journal-title":"J. Clin. Investig."},{"key":"1079_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3390\/ijms23010423","volume":"23","author":"F Yesmin","year":"2021","unstructured":"Yesmin, F. et al. Ganglioside GD2 enhances the malignant phenotypes of melanoma cells by cooperating with integrins. Int. J. Mol. Sci. 23, 423 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1079_CR12","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.1038\/s41598-023-31216-4","volume":"13","author":"F Yesmin","year":"2023","unstructured":"Yesmin, F. et al. Extracellular vesicles released from ganglioside GD2-expressing melanoma cells enhance the malignant properties of GD2-negative melanomas. Sci. Rep. 13, 4987 (2023).","journal-title":"Sci. Rep."},{"key":"1079_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/biom9080311","volume":"9","author":"S Cavdarli","year":"2019","unstructured":"Cavdarli, S., Groux-Degroote, S. & Delannoy, P. Gangliosides: the double-edge sword of neuro-ectodermal derived tumors. Biomolecules 9, 311 (2019).","journal-title":"Biomolecules"},{"key":"1079_CR14","first-page":"4244","volume":"61","author":"S Yoshida","year":"2001","unstructured":"Yoshida, S. et al. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 61, 4244\u20134252 (2001).","journal-title":"Cancer Res."},{"key":"1079_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/156800910791054167","volume":"10","author":"F Navid","year":"2010","unstructured":"Navid, F., Santana, V. M. & Barfield, R. C. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr. Cancer Drug Targets. 10, 200\u20139 (2010).","journal-title":"Curr. Cancer Drug Targets."},{"key":"1079_CR16","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1182\/blood-2006-08-039347","volume":"109","author":"C Martinez","year":"2007","unstructured":"Martinez, C., Hofmann, T. J., Marino, R., Dominici, M. & Horwitz, E. M. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 109, 4245\u20134248 (2007).","journal-title":"Blood"},{"key":"1079_CR17","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1111\/j.1471-4159.1991.tb03466.x","volume":"56","author":"L Svennerholm","year":"1991","unstructured":"Svennerholm, L., Bostr\u00f6m, K., Helander, C. G. & Jungbjer, B. Membrane lipids in the aging human brain. J. Neurochem. 56, 2051\u20132059 (1991).","journal-title":"J. Neurochem."},{"key":"1079_CR18","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1074\/jbc.RA118.002763","volume":"294","author":"RJE van den Bijgaart","year":"2019","unstructured":"van den Bijgaart, R. J. E. et al. Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2. J. Biol. Chem. 294, 4437\u20134449 (2019).","journal-title":"J. Biol. Chem."},{"key":"1079_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0005-2760(89)90175-6","volume":"1005","author":"L Svennerholm","year":"1989","unstructured":"Svennerholm, L. et al. Human brain gangliosides: developmental changes from early fetal stage to advanced age. Biochim. Biophys. Acta 1005, 109\u2013117 (1989).","journal-title":"Biochim. Biophys. Acta"},{"key":"1079_CR20","doi-asserted-by":"publisher","first-page":"572965","DOI":"10.3389\/fnins.2020.572965","volume":"14","author":"S Sipione","year":"2020","unstructured":"Sipione, S., Monyror, J., Galleguillos, D., Steinberg, N. & Kadam, V. Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front. Neurosci. 14, 572965 (2020).","journal-title":"Front. Neurosci."},{"key":"1079_CR21","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00018-010-0292-z","volume":"67","author":"HJ Jin","year":"2010","unstructured":"Jin, H. J. et al. GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells. Cell. Mol. Life Sci. 67, 1845\u20131858 (2010).","journal-title":"Cell. Mol. Life Sci."},{"key":"1079_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5650\/jos.60.537","volume":"60","author":"RK Yu","year":"2011","unstructured":"Yu, R. K., Tsai, Y.-T., Ariga, T. & Yanagisawa, M. Structures, biosynthesis, and functions of gangliosides\u2013an overview. J. Oleo Sci. 60, 537\u2013544 (2011).","journal-title":"J. Oleo Sci."},{"key":"1079_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1","volume":"73","author":"S Zhang","year":"1997","unstructured":"Zhang, S. et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 73, 42\u201349 (1997).","journal-title":"Int. J. Cancer"},{"key":"1079_CR24","first-page":"2857","volume":"49","author":"K Mujoo","year":"1989","unstructured":"Mujoo, K. et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 49, 2857\u20132861 (1989).","journal-title":"Cancer Res."},{"key":"1079_CR25","first-page":"114","volume":"4","author":"N Berois","year":"2014","unstructured":"Berois, N. & Osinaga, E. Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies. Front. Oncol. 4, 114 (2014).","journal-title":"Front. Oncol."},{"key":"1079_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2741\/s281","volume":"4","author":"DMS Hossain","year":"2012","unstructured":"Hossain, D. M. S., Mohanty, S., Ray, P., Das, T. & Sa, G. Tumor gangliosides and T cells: a deadly encounter. Front. Biosci. 4, 502\u2013519 (2012).","journal-title":"Front. Biosci."},{"key":"1079_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-0-387-72005-0_20","volume":"601","author":"M Potapenko","year":"2007","unstructured":"Potapenko, M., Shurin, G. V. & de Le\u00f3n, J. Gangliosides as immunomodulators. Adv. Exp. Med. Biol. 601, 195\u2013203 (2007).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1079_CR28","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ijc.2910530614","volume":"53","author":"J Portoukalian","year":"1993","unstructured":"Portoukalian, J., David, M. J., Gain, P. & Richard, M. Shedding of GD2 ganglioside in patients with retinoblastoma. Int. J. Cancer 53, 948\u2013951 (1993).","journal-title":"Int. J. Cancer"},{"key":"1079_CR29","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1182\/blood.V75.7.1564.1564","volume":"75","author":"L Valentino","year":"1990","unstructured":"Valentino, L. et al. Shed tumor gangliosides and progression of human neuroblastoma. Blood 75, 1564\u20131567 (1990).","journal-title":"Blood"},{"key":"1079_CR30","doi-asserted-by":"publisher","first-page":"e28031","DOI":"10.1002\/pbc.28031","volume":"67","author":"FM Balis","year":"2019","unstructured":"Balis, F. M. et al. The ganglioside G(D2) as a circulating tumor biomarker for neuroblastoma. Pediatr. Blood Cancer 67, e28031 (2019).","journal-title":"Pediatr. Blood Cancer"},{"key":"1079_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF00731471","volume":"13","author":"R Li","year":"1996","unstructured":"Li, R., Gage, D., McKallip, R. & Ladisch, S. Structural characterization and in vivo immunosuppressive activity of neuroblastoma GD2. Glycoconj. J. 13, 385\u2013389 (1996).","journal-title":"Glycoconj. J."},{"key":"1079_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/biomedicines8060142","volume":"8","author":"M Sorokin","year":"2020","unstructured":"Sorokin, M. et al. RNA sequencing-based identification of ganglioside GD2-positive cancer phenotype. Biomedicines 8, 142 (2020).","journal-title":"Biomedicines"},{"key":"1079_CR33","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/cancers14051299","volume":"14","author":"A Kasprowicz","year":"2022","unstructured":"Kasprowicz, A., Sophie, G.-D., Lagadec, C. & Delannoy, P. Role of GD3 synthase ST8Sia I in cancers. Cancers 14, 1299 (2022).","journal-title":"Cancers"},{"key":"1079_CR34","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","volume":"3","author":"NW Mabe","year":"2022","unstructured":"Mabe, N. W. et al. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. Nat. Cancer 3, 976\u2013993 (2022).","journal-title":"Nat. Cancer"},{"key":"1079_CR35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13046-022-02523-x","volume":"41","author":"Y-L Sha","year":"2022","unstructured":"Sha, Y.-L. et al. B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met\/AKT\/mTOR\/IRF-1 axis in neuroblastoma. J. Exp. Clin. Cancer Res. 41, 314 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1079_CR36","first-page":"e1394","volume":"4","author":"M Wiebel","year":"2022","unstructured":"Wiebel, M. et al. Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency. Cancer Rep (Hoboken). 4, e1394 (2022).","journal-title":"Cancer Rep (Hoboken)."},{"key":"1079_CR37","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-23-1880","volume":"30","author":"R Ciccone","year":"2024","unstructured":"Ciccone, R. et al. GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma. Clin. Cancer Res. 30, 2545\u20132557 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1079_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-024-01641-7","volume":"17","author":"M Pezzella","year":"2024","unstructured":"Pezzella, M. et al. Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. J. Hematol. Oncol. 17, 127 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1079_CR39","doi-asserted-by":"publisher","first-page":"103199","DOI":"10.1016\/j.xpro.2024.103199","volume":"5","author":"S Kailayangiri","year":"2024","unstructured":"Kailayangiri, S. et al. Protocol for assessing GD2 on formalin-fixed paraffin-embedded tissue sections using immunofluorescence staining. STAR Protoc. 5, 103199 (2024).","journal-title":"STAR Protoc."},{"key":"1079_CR40","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever, M. A. et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323\u20135337 (2009).","journal-title":"Clin. Cancer Res"},{"key":"1079_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jocn.2022.05.006","volume":"101","author":"SJ Liu","year":"2022","unstructured":"Liu, S. J. et al. Paediatric brain tumours in Singapore: a 15-year epidemiological and outcome study. J. Clin. Neurosci. 101, 154\u2013161 (2022).","journal-title":"J. Clin. Neurosci."},{"key":"1079_CR42","unstructured":"Subramanian, S. & Ahmad, T. Childhood brain tumors. in StatPearls (StatPearls Publishing, 2024)."},{"key":"1079_CR43","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3171\/2018.10.PEDS18377","volume":"23","author":"IF Pollack","year":"2019","unstructured":"Pollack, I. F., Agnihotri, S. & Broniscer, A. Childhood brain tumors: current management, biological insights, and future directions. J. Neurosurg. Pediatrics 23, 261\u2013273 (2019).","journal-title":"J. Neurosurg. Pediatrics"},{"key":"1079_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1750-3639.1993.tb00752.x","volume":"3","author":"P Kleihues","year":"1993","unstructured":"Kleihues, P., Burger, P. C. & Scheithauer, B. W. The new WHO classification of brain tumours. Brain Pathol. 3, 255\u2013268 (1993).","journal-title":"Brain Pathol."},{"key":"1079_CR45","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1002\/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F","volume":"88","author":"P Kleihues","year":"2000","unstructured":"Kleihues, P. & Sobin, L. H. World Health Organization classification of tumors. Cancer 88, 2887 (2000).","journal-title":"Cancer"},{"key":"1079_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97\u2013109 (2007).","journal-title":"Acta Neuropathol."},{"key":"1079_CR47","unstructured":"Z\u00fclch, K. J. Histological Typing of Tumours of the Central Nervous System (World Health Organization, 1979)."},{"key":"1079_CR48","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis, D. N. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131, 803\u2013820 (2016).","journal-title":"Acta Neuropathol."},{"key":"1079_CR49","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"1079_CR50","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro Oncol. 24, v1\u2013v95 (2022).","journal-title":"Neuro Oncol."},{"key":"1079_CR51","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","volume":"36","author":"LM Hoffman","year":"2018","unstructured":"Hoffman, L. M. et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG registries. J. Clin. Oncol. 36, 1963\u20131972 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1079_CR52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40478-020-00913-w","volume":"8","author":"R-C Chai","year":"2020","unstructured":"Chai, R.-C. et al. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathol. Commun. 8, 40 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"1079_CR53","doi-asserted-by":"publisher","first-page":"e13153","DOI":"10.1111\/bpa.13153","volume":"33","author":"R-C Chai","year":"2023","unstructured":"Chai, R.-C. et al. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma. Brain Pathol. 33, e13153 (2023).","journal-title":"Brain Pathol."},{"key":"1079_CR54","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay, A. et al. Integrated molecular meta-analysis of 1000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32, 520\u2013537.e5 (2017).","journal-title":"Cancer Cell"},{"key":"1079_CR55","doi-asserted-by":"crossref","unstructured":"Szychot, E. et al. European standard clinical practice recommendations for paediatric high-grade gliomas. EJC Paediatr. Oncol. 5, 100210 (2025).","DOI":"10.1016\/j.ejcped.2024.100210"},{"key":"1079_CR56","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/neuonc\/noac103","volume":"24","author":"B Purow","year":"2022","unstructured":"Purow, B. ONC201 and ONC206: metabolically ClipPing the wings of diffuse midline glioma. Neuro Oncol. 24, 1452\u20131453 (2022).","journal-title":"Neuro Oncol."},{"key":"1079_CR57","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/neuonc\/noad141","volume":"25","author":"M Monje","year":"2023","unstructured":"Monje, M. et al. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium (PBTC-047). Neuro Oncol. 25, 2262\u20132272 (2023).","journal-title":"Neuro Oncol."},{"key":"1079_CR58","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"1079_CR59","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza, N. A. et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 13, 114\u2013131 (2023).","journal-title":"Cancer Discov."},{"key":"1079_CR60","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza, N. A. et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat. Med. 31, 861\u2013868 (2025).","journal-title":"Nat. Med."},{"key":"1079_CR61","first-page":"vdab061","volume":"3","author":"T Picart","year":"2021","unstructured":"Picart, T. et al. Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. Neurooncol. Adv. 3, vdab061 (2021).","journal-title":"Neurooncol. Adv."},{"key":"1079_CR62","doi-asserted-by":"crossref","unstructured":"Chen, K. Y. et al. Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling. Commun. Biol. 3, 363 (2020).","DOI":"10.1038\/s42003-020-1076-0"},{"key":"1079_CR63","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.ccell.2024.08.006","volume":"42","author":"I Liu","year":"2024","unstructured":"Liu, I. et al. GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant. Cancer Cell 42, 1528\u20131548.e17 (2024).","journal-title":"Cancer Cell"},{"key":"1079_CR64","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas letter. Nat. Med. 24, 572\u2013579 (2018).","journal-title":"Nat. Med."},{"key":"1079_CR65","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/neuonc\/noab300","volume":"24","author":"E De Billy","year":"2022","unstructured":"De Billy, E. et al. Dual IGF1R\/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro Oncol. 24, 1150\u20131163 (2022).","journal-title":"Neuro Oncol."},{"key":"1079_CR66","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","volume":"23","author":"D Haydar","year":"2021","unstructured":"Haydar, D. et al. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro Oncol. 23, 999\u20131011 (2021).","journal-title":"Neuro Oncol."},{"key":"1079_CR67","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/cncr.29907","volume":"122","author":"R Krishnatry","year":"2016","unstructured":"Krishnatry, R. et al. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer 122, 1261\u20131269 (2016).","journal-title":"Cancer"},{"key":"1079_CR68","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00401-015-1410-7","volume":"129","author":"VP Collins","year":"2015","unstructured":"Collins, V. P., Jones, D. T. W. & Giannini, C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 129, 775\u2013788 (2015).","journal-title":"Acta Neuropathol."},{"key":"1079_CR69","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1097\/01.jnen.0000240465.33628.87","volume":"65","author":"DTW Jones","year":"2006","unstructured":"Jones, D. T. W. et al. Genomic analysis of pilocytic astrocytomas at 0.97\u2009Mb resolution shows an increasing tendency toward chromosomal copy number change with age. J. Neuropathol. Exp. Neurol. 65, 1049\u20131058 (2006).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1079_CR70","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ng.2611","volume":"45","author":"J Zhang","year":"2013","unstructured":"Zhang, J. et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 45, 602\u2013612 (2013).","journal-title":"Nat. Genet."},{"key":"1079_CR71","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00401-016-1539-z","volume":"131","author":"I Qaddoumi","year":"2016","unstructured":"Qaddoumi, I. et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 131, 833\u2013845 (2016).","journal-title":"Acta Neuropathol."},{"key":"1079_CR72","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s007010050439","volume":"141","author":"R Wagener","year":"1999","unstructured":"Wagener, R. et al. Ganglioside profiles in human gliomas: quantification by microbore high performance liquid chromatography and correlation to histomorphology and grading. Acta Neurochir. 141, 1339\u20131345 (1999).","journal-title":"Acta Neurochir."},{"key":"1079_CR73","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.1007\/s00216-013-7173-x","volume":"405","author":"AD Zamfir","year":"2013","unstructured":"Zamfir, A. D. et al. Profiling and sequence analysis of gangliosides in human astrocytoma by high-resolution mass spectrometry. Anal. Bioanal. Chem. 405, 7321\u20137335 (2013).","journal-title":"Anal. Bioanal. Chem."},{"key":"1079_CR74","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2016.01.015","volume":"164","author":"D Sturm","year":"2016","unstructured":"Sturm, D. et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164, 1060\u20131072 (2016).","journal-title":"Cell"},{"key":"1079_CR75","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.21873\/anticanres.15703","volume":"42","author":"T Sursal","year":"2022","unstructured":"Sursal, T. et al. Molecular stratification of medulloblastoma: clinical outcomes and therapeutic interventions. Anticancer Res. 42, 2225\u20132239 (2022).","journal-title":"Anticancer Res."},{"key":"1079_CR76","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","volume":"123","author":"MD Taylor","year":"2011","unstructured":"Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123, 465\u2013472 (2011).","journal-title":"Acta Neuropathol."},{"key":"1079_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14246051","volume":"14","author":"C Paret","year":"2022","unstructured":"Paret, C. et al. GD2 expression in medulloblastoma and neuroblastoma for personalized immunotherapy: a matter of subtype. Cancers 14, 1\u201322 (2022).","journal-title":"Cancers"},{"key":"1079_CR78","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/neuonc\/noz235","volume":"22","author":"B Ho","year":"2020","unstructured":"Ho, B. et al. Molecular subgrouping of atypical teratoid\/rhabdoid tumors-a reinvestigation and current consensus. Neuro Oncol. 22, 613\u2013624 (2020).","journal-title":"Neuro Oncol."},{"key":"1079_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2991\/jegh.k.181224.001","volume":"9","author":"HM Alkatan","year":"2019","unstructured":"Alkatan, H. M., Al Marek, F. & Elkhamary, S. Demographics of pediatric orbital lesions: a tertiary eye center experience in Saudi Arabia. J. Epidemiol. Glob. Health 9, 3\u201310 (2019).","journal-title":"J. Epidemiol. Glob. Health"},{"key":"1079_CR80","first-page":"103","volume":"4","author":"J Yun","year":"2011","unstructured":"Yun, J., Li, Y., Xu, C.-T. & Pan, B.-R. Epidemiology and Rb1 gene of retinoblastoma. Int. J. Ophthalmol. 4, 103\u2013109 (2011).","journal-title":"Int. J. Ophthalmol."},{"key":"1079_CR81","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1111\/febs.16035","volume":"289","author":"M Mart\u00ednez-S\u00e1nchez","year":"2021","unstructured":"Mart\u00ednez-S\u00e1nchez, M., Hernandez-Monge, J., Rangel, M. & Olivares-Illana, V. Retinoblastoma: from discovery to clinical management. FEBS J. 289, 4371\u20134382 (2021).","journal-title":"FEBS J."},{"key":"1079_CR82","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.4103\/ijo.IJO_721_20","volume":"68","author":"D Ancona-Lezama","year":"2020","unstructured":"Ancona-Lezama, D., Dalvin, L. A. & Shields, C. L. Modern treatment of retinoblastoma: a 2020 review. Indian J. Ophthalmol. 68, 2356\u20132365 (2020).","journal-title":"Indian J. Ophthalmol."},{"key":"1079_CR83","doi-asserted-by":"crossref","unstructured":"Andersch, L. et al. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer 19, 895 (2019).","DOI":"10.1186\/s12885-019-6131-1"},{"key":"1079_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.01000","volume":"10","author":"B Nazha","year":"2020","unstructured":"Nazha, B., Inal, C. & Owonikoko, T. K. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front. Oncol. 10, 1\u201315 (2020).","journal-title":"Front. Oncol."},{"key":"1079_CR85","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41416-022-01855-x","volume":"127","author":"MJ Stagno","year":"2022","unstructured":"Stagno, M. J. et al. Epitope detection in monocytes (EDIM) for liquid biopsy including identification of GD2 in childhood neuroblastoma-a pilot study. Br. J. Cancer 127, 1324\u20131331 (2022).","journal-title":"Br. J. Cancer"},{"key":"1079_CR86","doi-asserted-by":"crossref","unstructured":"Morini, M. et al. Detection of plasma circulating GD2 ganglioside in patients with neuroblastoma and age-matched healthy children. Diagnostic and prognostic evaluation. Oncologist 30, oyaf008 (2025).","DOI":"10.1093\/oncolo\/oyaf008"},{"key":"1079_CR87","doi-asserted-by":"publisher","first-page":"1134763","DOI":"10.3389\/fonc.2023.1134763","volume":"13","author":"A Galan","year":"2023","unstructured":"Galan, A. et al. GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer. Front. Oncol. 13, 1134763 (2023).","journal-title":"Front. Oncol."},{"key":"1079_CR88","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/PAI.0000000000000974","volume":"30","author":"E Zhong","year":"2022","unstructured":"Zhong, E. et al. Expression analysis of GD2 by immunohistochemistry in invasive breast carcinoma: clinical and pathologic correlation. Appl. Immunohistochem. Mol. Morphol. 30, 113\u2013118 (2022).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"1079_CR89","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4081\/ejh.2010.e23","volume":"54","author":"T Petr","year":"2010","unstructured":"Petr, T. et al. Histochemical detection of GM1 ganglioside using cholera toxin- B subunit. Evaluation of critical factors optimal for in situ detection with special emphasis to acetone pre-extraction. Eur. J. Histochem. 54, 112\u2013117 (2010).","journal-title":"Eur. J. Histochem."},{"key":"1079_CR90","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/1097-0142(20010815)92:4<924::AID-CNCR1402>3.0.CO;2-O","volume":"92","author":"MSLo Piccolo","year":"2001","unstructured":"Piccolo, M. S. L. o, Cheung, N. K. V. & Cheung, I. Y. GD2 synthase: a new molecular marker for detecting neuroblastoma. Cancer 92, 924\u2013931 (2001).","journal-title":"Cancer"},{"key":"1079_CR91","first-page":"5395","volume":"53","author":"S Yamashiro","year":"1993","unstructured":"Yamashiro, S. et al. Genetic and enzymatic basis for the differential expression of GM2 and GD2 gangliosides in human cancer cell lines. Cancer Res. 53, 5395\u20135400 (1993).","journal-title":"Cancer Res."},{"key":"1079_CR92","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.1987.5.9.1430","volume":"5","author":"NK Cheung","year":"1987","unstructured":"Cheung, N. K. et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol. 5, 1430\u20131440 (1987).","journal-title":"J. Clin. Oncol."},{"key":"1079_CR93","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","volume":"30","author":"N-KV Cheung","year":"2012","unstructured":"Cheung, N.-K. V. et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J. Clin. Oncol. 30, 3264\u20133270 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1079_CR94","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4161\/mabs.4.1.18566","volume":"4","author":"G Soman","year":"2012","unstructured":"Soman, G. et al. Analytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody. MAbs 4, 84\u2013100 (2012).","journal-title":"MAbs"},{"key":"1079_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-295","volume":"14","author":"II Doronin","year":"2014","unstructured":"Doronin, I. I. et al. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer 14, 295 (2014).","journal-title":"BMC Cancer"},{"key":"1079_CR96","doi-asserted-by":"crossref","unstructured":"Horta, Z. P., Goldberg, J. L. & Sondel, P. M. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy 8, 1097\u20131117 (2016).","DOI":"10.2217\/imt-2016-0021"},{"key":"1079_CR97","doi-asserted-by":"publisher","first-page":"7394268","DOI":"10.1155\/2018\/7394268","volume":"2018","author":"IV Kholodenko","year":"2018","unstructured":"Kholodenko, I. V., Kalinovsky, D. V., Doronin Igor, I., Deyev, S. M. & Kholodenko, R. V. Neuroblastoma origin and therapeutic targets for immunotherapy. J. Immunol. Res. 2018, 7394268 (2018).","journal-title":"J. Immunol. Res."},{"key":"1079_CR98","doi-asserted-by":"publisher","first-page":"41172","DOI":"10.18632\/oncotarget.9226","volume":"7","author":"J Fleurence","year":"2016","unstructured":"Fleurence, J. et al. Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside. Oncotarget 7, 41172\u201341185 (2016).","journal-title":"Oncotarget"},{"key":"1079_CR99","doi-asserted-by":"crossref","unstructured":"Kramer, K. et al. A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma. Pediatr. Blood Cancer 65, (2017).","DOI":"10.1002\/pbc.26754"},{"key":"1079_CR100","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11033-020-05995-2","volume":"48","author":"M Mirian","year":"2021","unstructured":"Mirian, M. et al. Generation of HBsAg DNA aptamer using modified cell-based SELEX strategy. Mol. Biol. Rep. 48, 139\u2013146 (2021).","journal-title":"Mol. Biol. Rep."},{"key":"1079_CR101","doi-asserted-by":"publisher","first-page":"e2003704","DOI":"10.1002\/adma.202003704","volume":"32","author":"AE Rangel","year":"2020","unstructured":"Rangel, A. E., Hariri, A. A., Eisenstein, M. & Soh, H. T. Engineering aptamer switches for multifunctional stimulus-responsive nanosystems. Adv. Mater. 32, e2003704 (2020).","journal-title":"Adv. Mater."},{"key":"1079_CR102","doi-asserted-by":"publisher","first-page":"9101","DOI":"10.3390\/ijms22169101","volume":"22","author":"GO Sabbih","year":"2021","unstructured":"Sabbih, G. O. & Danquah, M. K. Neuroblastoma GD2 expression and computational analysis of aptamer-based bioaffinity targeting. Int. J. Mol. Sci. 22, 9101 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1079_CR103","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.2147\/IJN.S302450","volume":"16","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. A novel pH-sensitive multifunctional DNA nanomedicine: an enhanced and harmless GD2 aptamer-mediated strategy for guiding neuroblastoma antitumor therapy. Int. J. Nanomed. 16, 3217\u20133240 (2021).","journal-title":"Int. J. Nanomed."},{"key":"1079_CR104","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.omtn.2021.08.021","volume":"26","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics. Mol. Ther. Nucleic Acids 26, 732\u2013748 (2021).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1079_CR105","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/1078-0432.CCR-13-1012","volume":"20","author":"BH Kushner","year":"2014","unstructured":"Kushner, B. H. et al. Phase I trial of a bivalent gangliosides vaccine in combination with \u03b2-glucan for high-risk neuroblastoma in second or later remission. Clin. Cancer Res. 20, 1375\u20131382 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1079_CR106","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1200\/JCO.20.01892","volume":"39","author":"IY Cheung","year":"2020","unstructured":"Cheung, I. Y. et al. Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression. J. Clin. Oncol. 39, 215\u2013226 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1079_CR107","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fonc.2012.00196","volume":"2","author":"T Kieber-Emmons","year":"2012","unstructured":"Kieber-Emmons, T. et al. The promise of the anti-idiotype concept. Front. Oncol. 2, 196 (2012).","journal-title":"Front. Oncol."},{"key":"1079_CR108","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.3390\/cancers14235802","volume":"14","author":"L Klingel","year":"2022","unstructured":"Klingel, L. et al. Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: results from compassionate-use treatments. Cancers 14, 5802 (2022).","journal-title":"Cancers"},{"key":"1079_CR109","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-013-1413-y","volume":"62","author":"HN Lode","year":"2013","unstructured":"Lode, H. N. et al. Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response. Cancer Immunol. Immunother. 62, 999\u20131010 (2013).","journal-title":"Cancer Immunol. Immunother."},{"key":"1079_CR110","doi-asserted-by":"publisher","first-page":"e0150479","DOI":"10.1371\/journal.pone.0150479","volume":"11","author":"C Eger","year":"2016","unstructured":"Eger, C. et al. Generation and characterization of a human\/mouse chimeric GD2-mimicking anti-idiotype antibody ganglidiximab for active immunotherapy against neuroblastoma. PLoS ONE 11, e0150479 (2016).","journal-title":"PLoS ONE"},{"key":"1079_CR111","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei, P. et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J. Clin. Investig. 126, 3363\u20133376 (2016).","journal-title":"J. Clin. Investig."},{"key":"1079_CR112","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38, 473\u2013488 (2020).","journal-title":"Cancer Cell"},{"key":"1079_CR113","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2174\/0113892010257212231001082741","volume":"25","author":"MZ Ong","year":"2024","unstructured":"Ong, M. Z. et al. FDA-approved CAR T-cell therapy: a decade of progress and challenges. Curr. Pharm. Biotechnol. 25, 1377\u20131393 (2024).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"1079_CR114","doi-asserted-by":"crossref","unstructured":"Anderson, J., Barone, G. & Zehner, A. GD2 targeting CAR T cells for neuroblastoma. EJC Paediatr. Oncol. 4, (2024).","DOI":"10.1016\/j.ejcped.2024.100179"},{"key":"1079_CR115","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050\u20136056 (2011).","journal-title":"Blood"},{"key":"1079_CR116","unstructured":"Che-Hsing, L. et al. Eighteen-year survival after GD2-directed chimeric antigen-modified immune effector cell treatment for neuroblastoma. Res. Sq 3, rs-4232549 (2024)."},{"key":"1079_CR117","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","volume":"35","author":"JR Park","year":"2017","unstructured":"Park, J. R. et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the National Cancer Institute clinical trials planning meeting. J. Clin. Oncol. 35, 2580\u20132587 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1079_CR118","doi-asserted-by":"publisher","first-page":"e1433518","DOI":"10.1080\/2162402X.2018.1433518","volume":"7","author":"C Quintarelli","year":"2018","unstructured":"Quintarelli, C. et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology 7, e1433518 (2018).","journal-title":"Oncoimmunology"},{"key":"1079_CR119","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1079_CR120","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","volume":"31","author":"C Quintarelli","year":"2025","unstructured":"Quintarelli, C. et al. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Nat. Med. 31, 849\u2013860 (2025).","journal-title":"Nat. Med."},{"key":"1079_CR121","doi-asserted-by":"publisher","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature https:\/\/doi.org\/10.1038\/s41586-024-08171-9 (2024).","DOI":"10.1038\/s41586-024-08171-9"},{"key":"1079_CR122","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin, H., Yang, X., Ye, S., Huang, L. & Mu, W. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed. Pharmacother. 178, 117252 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"1079_CR123","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ijc.2910500207","volume":"50","author":"JN Ye","year":"1992","unstructured":"Ye, J. N. & Cheung, N.-K. V. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies. Int. J. Cancer 50, 197\u2013201 (1992).","journal-title":"Int. J. Cancer"},{"key":"1079_CR124","doi-asserted-by":"publisher","first-page":"e25220","DOI":"10.1371\/journal.pone.0025220","volume":"6","author":"N Alvarez-Rueda","year":"2011","unstructured":"Alvarez-Rueda, N., Desselle, A., Cochonneau, D., Chaumette, T. & Clemenceau, B. A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity. PLoS ONE 6, e25220 (2011).","journal-title":"PLoS ONE"},{"key":"1079_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49595-1","volume":"15","author":"AB Levine","year":"2024","unstructured":"Levine, A. B. et al. Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment. Nat. Commun. 15, 5790 (2024).","journal-title":"Nat. Commun."},{"key":"1079_CR126","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu, A. L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324\u20131334 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1079_CR127","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","volume":"27","author":"AL Yu","year":"2021","unstructured":"Yu, A. L. et al. Long-term follow-up of a phase III study of ch14.18 (Dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clin. Cancer Res. 27, 2179\u20132189 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1079_CR128","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4161\/onci.19864","volume":"1","author":"N-KV Cheung","year":"2012","unstructured":"Cheung, N.-K. V., Guo, H., Hu, J., Tassev, D. V. & Cheung, I. Y. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 1, 477\u2013486 (2012).","journal-title":"Oncoimmunology"},{"key":"1079_CR129","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","volume":"19","author":"A Italiano","year":"2018","unstructured":"Italiano, A. et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 19, 649\u2013659 (2018).","journal-title":"Lancet Oncol."},{"key":"1079_CR130","doi-asserted-by":"publisher","first-page":"2240678","DOI":"10.1080\/2162402X.2023.2240678","volume":"12","author":"AA Pilgrim","year":"2023","unstructured":"Pilgrim, A. A. et al. The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1. Oncoimmunology 12, 2240678 (2023).","journal-title":"Oncoimmunology"},{"key":"1079_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54689-x","volume":"15","author":"JRC Rouaen","year":"2024","unstructured":"Rouaen, J. R. C. et al. Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma. Nat. Commun. 15, 10462 (2024).","journal-title":"Nat. Commun."},{"key":"1079_CR132","doi-asserted-by":"publisher","first-page":"e000540","DOI":"10.1136\/jitc-2020-000540","volume":"8","author":"K Ehlert","year":"2020","unstructured":"Ehlert, K. et al. Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma. J. Immunother Cancer 8, e000540 (2020).","journal-title":"J. Immunother Cancer"},{"key":"1079_CR133","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi, J. et al. Tumor inflammation-associated neurotoxicity. Nat. Med. 29, 803\u2013810 (2023).","journal-title":"Nat. Med."},{"key":"1079_CR134","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637, 708\u2013715 (2025).","journal-title":"Nature"},{"key":"1079_CR135","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10555-024-10227-1","volume":"44","author":"AW Rankin","year":"2025","unstructured":"Rankin, A. W., Duncan, B. B., Allen, C., Silbert, S. K. & Shah, N. N. Evolving strategies for addressing CAR T-cell toxicities. Cancer Metastasis Rev. 44, 17 (2025).","journal-title":"Cancer Metastasis Rev."},{"key":"1079_CR136","doi-asserted-by":"crossref","unstructured":"Chang, F., Li, R., Noon, K., Gage, D. & Ladisch, S. Human Medulloblastoma Gangliosides. vol. 7 https:\/\/academic.oup.com\/glycob\/article\/7\/4\/523\/653473 (1997).","DOI":"10.1093\/glycob\/7.4.523"},{"key":"1079_CR137","doi-asserted-by":"publisher","first-page":"31592","DOI":"10.18632\/oncotarget.16363","volume":"8","author":"G Orsi","year":"2017","unstructured":"Orsi, G. et al. GD2 expression in breast cancer. Oncotarget 8, 31592\u201331600 (2017).","journal-title":"Oncotarget"},{"key":"1079_CR138","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/15513815.2019.1588439","volume":"38","author":"Z Ayg\u00fcn","year":"2019","unstructured":"Ayg\u00fcn, Z. et al. Frequency of ALK and GD2 expression in neuroblastoma. Fetal Pediatr. Pathol. 38, 326\u2013334 (2019).","journal-title":"Fetal Pediatr. Pathol."},{"key":"1079_CR139","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejmech.2018.02.082","volume":"150","author":"M Palacios","year":"2018","unstructured":"Palacios, M. et al. Antitumor activity and carrier properties of novel hemocyanins coupled to a mimotope of GD2 ganglioside. Eur. J. Med. Chem. 150, 74\u201386 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"1079_CR140","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MPH.0000000000001369","volume":"41","author":"J Voeller","year":"2019","unstructured":"Voeller, J. & Sondel, P. M. Advances in Anti-GD2 immunotherapy for treatment of high-risk neuroblastoma. J. Pediatr. Hematol. Oncol. 41, 163\u2013169 (2019).","journal-title":"J. Pediatr. Hematol. Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01079-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:18:54Z","timestamp":1757413134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01079-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":140,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1079"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01079-1","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}